Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Neoplasm Recurrence, Local 1Lung Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 504Cyclophosphamide 353Radiotherapy 349Carboplatin 347Capecitabine 328Oxaliplatin 319Paclitaxel 316Gemcitabine 315Docetaxel 308Fluorouracil 281apatinib 240Drug Therapy 239Bevacizumab 224camrelizumab 212Etoposide 199Irinotecan 176Doxorubicin 174Dexamethasone 159Leucovorin 158sintilimab 140Pemetrexed 136Cytarabine 136pembrolizumab 135anlotinib 135toripalimab 124S 1 (combination) 119Neoadjuvant Therapy 119Vincristine 118Rituximab 114Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Interventional × Rhenium × Clear all
NCT00100256 2022-11-07

Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy

Andarix Pharmaceuticals

Phase 1/2 Unknown
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Recurrence, Local, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡